Advertisement

Topics

Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin

07:41 EDT 20 Mar 2017 | BioPharmaDive

In a so-called real world study, the anti-coagulant did better in reducing the risk of strokes or major bleeds compared to warfarin than did J&J's competing Xarelto or Boehringer's Pradaxa. 

Original Article: Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin"

Quick Search
Advertisement